News

New breakthrough in MegaPro’s Iron Supplements Benefit Kidney Disease Patients

New breakthrough in MegaPro’s Iron Supplements Benefit Kidney Disease Patients

      New breakthrough in iron supplements developed in Taiwan for chronic kidney disease has been made!  The IOP Injection Nano Iron Oxide made by MegaPro Biomedical, a new biotechnology company of ITRI, has completed animal drug experiments and safety assessments and is about to enter the first phase of clinical trials, preparing to take huge strides toward the goal of new drug listings.  The first new drug is expected to be launched in 2019, which provides rapid and effective iron supplements for patients with chronic kidney disease.

      Wang Yueru, director of MegaPro Biomedical Regulations, said that after branching out from ITRI in 2015, through the team's efforts, MegaPro Biomedical has completed the drug manufacturing, non-clinical effectiveness and safety discussions, legal regulations and other restrictions within one year.  This year, it was selected as an index case by the Center for Drug Inspection (CDE). Last month, it was also evaluated by the Industrial Development Bureau as complying with the Biotechnology and New Drug Industry Development Regulations. In the same month, it began its partnership with the Taipei Veterans General Hospital to conduct the IOP Injection Phase I clinical trial.

      MegaPro Biomedical is very excited about the rapid progress of its drug verification. Wang Yueru indicated that as MegaPro Biomedical faces verifications of safety and effectiveness of the IOP Injection nano iron oxide drugs, prospects are bright and highly anticipated.  MegaPro Biomedical will soon enter the second phase of clinical trials and start fundraising for the new stage ahead.

      Dr. Jassy Wang, general manager of MegaPro Biomedical remarked that the market for iron supplements for patients with kidney disease is immense, and the world's intravenous iron supplements market can reach up to more than US$1.6 billion annually. The IOP Injection Nano Iron Oxide drug from MegaPro Biomedical can be used to replenish iron in a single injection without the need for fractional treatment to meet the rapidly increasing iron supplement needs.

      Wang Xianzhi pointed out that MegaPro Biomedical will focus on the development of niche drugs in the future, focusing on the value added in the pre-clinical and human clinical trials, providing nanoparticles and nanocell front-end biotechnology companies, and licensing the products to pharmaceutical companies and becoming the outlet of Taiwan's nano-drugs in the future.

source: http://www.chinatimes.com/newspapers/20160229000143-260210